semaglutide and cardiovascular outcomes in obesity without diabetes journal club GLP-1 receptor agonists can reduce the risk of adverse events pts with diabetes. Whether the GLP-1 receptor agonist can also reduce cardiovascular risk in pts with overweight or Semaglutide and cardiovascular outcomes in

We used the risk in the placebo group, along with the pooled relative risk for overall patients at long-term follow-up from the systematic review, to calculate the absolute effect estimates in our evidence summaries

This section is offered to provide clinicians and patients with a framework and strategy for determining optimal treatment approaches (see Figure 1)

The reduction in blood pressure happens earlier than we expect if it was all due to weight loss, says Luke Laffin MD, co-director of the Blood Pressure Disorders Center at Cleveland Clinic in Ohio

[Accessed 19 January 2026]

However, the findings and conclusions presented in this paper are those of the authors and do not necessarily reflect the views of the NIH or the U.S